Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes

Avid Bioservices Announces Proposed Private Placement of Convertible Notes

Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023

Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility

Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference